A Multicenter Phase 2 Trial of Praltrexate W/Relapsed

O'Connor, Owen

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: Food and Drug Administration (FDA)
• Type: Research Project (R01)
• Project #: 1R01FD003498-01
• Application #: 7491390
• Study Section: Special Emphasis Panel (ZFD1-OPD-L (01))
• Program Officer: Ganti, Usha
• Project Start: 2007-09-30
• Project End: 2010-09-29
• Budget Start: 2007-09-30
• Budget End: 2008-09-29
• Support Year: 1
• Fiscal Year: 2007

Institution

• Name: Columbia University (N.Y.)
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 621889815
• City: New York
• State: NY
• Country: United States
• Zip Code: 10032

Publications

O'Connor, Owen A; Pro, Barbara; Pinter-Brown, Lauren et al. (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29:1182-9

Marchi, Enrica; Paoluzzi, Luca; Scotto, Luigi et al. (2010) Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 16:3648-58

Mould, D R; Sweeney, K; Duffull, S B et al. (2009) A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther 86:190-6